Cargando…

Molecular features of glioblastomas in long-term survivors compared to short-term survivors—a matched-pair analysis

BACKGROUND: Although glioblastoma (GB) is associated with a devastating prognosis, a small proportion of patients achieve long-term survival rates. We herein present a matched-pair analysis of molecular factors found in long- and short-term survivors (LTS, STS). METHODS: We performed a cross-institu...

Descripción completa

Detalles Bibliográficos
Autores principales: Sommerlath, Vivien N., Buergy, Daniel, Etminan, Nima, Brehmer, Stefanie, Reuss, David, Sarria, Gustavo R., Guiot, Marie-Christin, Hänggi, Daniel, Wenz, Frederik, Petrecca, Kevin, Giordano, Frank A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8785532/
https://www.ncbi.nlm.nih.gov/pubmed/35073955
http://dx.doi.org/10.1186/s13014-022-01984-w
_version_ 1784638983152599040
author Sommerlath, Vivien N.
Buergy, Daniel
Etminan, Nima
Brehmer, Stefanie
Reuss, David
Sarria, Gustavo R.
Guiot, Marie-Christin
Hänggi, Daniel
Wenz, Frederik
Petrecca, Kevin
Giordano, Frank A.
author_facet Sommerlath, Vivien N.
Buergy, Daniel
Etminan, Nima
Brehmer, Stefanie
Reuss, David
Sarria, Gustavo R.
Guiot, Marie-Christin
Hänggi, Daniel
Wenz, Frederik
Petrecca, Kevin
Giordano, Frank A.
author_sort Sommerlath, Vivien N.
collection PubMed
description BACKGROUND: Although glioblastoma (GB) is associated with a devastating prognosis, a small proportion of patients achieve long-term survival rates. We herein present a matched-pair analysis of molecular factors found in long- and short-term survivors (LTS, STS). METHODS: We performed a cross-institutional analysis of 262 patient records and matched a group of 91 LTS (≥ 3 years) with two groups of STS (STS-1, n = 91; STS-2, n = 80). Matching was performed according to age, Karnofsky Performance Status, initial therapy and adjuvant therapy. Molecular factors were compared between LTS (total of 91 patients) v. STS-1, and LTS (subgroup of 80 patients) v. STS-2. We included glial fibrillary acidic protein (GFAP), O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation, isocitrate dehydrogenase 1 (IDH-1); furthermore, the proliferation index was analyzed (Ki-67/MIB-1). RESULTS: IDH-1 and decreased Ki-67 were numerically associated with LTS but the difference was only significant compared to STS-1 (n.s. v. STS-2). LTS was associated with MGMT promoter hypermethylation (p = 0.013 and p = 0.022) and GFAP expression (p < 0.001 and p = 0.001). Positivity for both factors combined compared to negativity for one factor occurred more often in the LTS group (p = 0.002 and p = 0.006); negativity for both factors combined did not occur in the LTS group. CONCLUSION: In this retrospective analysis, GFAP expression and MGMT promoter methylation were associated with LTS. Given the hypothesis-generating nature of our study, these observations should be confirmed in prospective clinical trials. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13014-022-01984-w.
format Online
Article
Text
id pubmed-8785532
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-87855322022-01-24 Molecular features of glioblastomas in long-term survivors compared to short-term survivors—a matched-pair analysis Sommerlath, Vivien N. Buergy, Daniel Etminan, Nima Brehmer, Stefanie Reuss, David Sarria, Gustavo R. Guiot, Marie-Christin Hänggi, Daniel Wenz, Frederik Petrecca, Kevin Giordano, Frank A. Radiat Oncol Research BACKGROUND: Although glioblastoma (GB) is associated with a devastating prognosis, a small proportion of patients achieve long-term survival rates. We herein present a matched-pair analysis of molecular factors found in long- and short-term survivors (LTS, STS). METHODS: We performed a cross-institutional analysis of 262 patient records and matched a group of 91 LTS (≥ 3 years) with two groups of STS (STS-1, n = 91; STS-2, n = 80). Matching was performed according to age, Karnofsky Performance Status, initial therapy and adjuvant therapy. Molecular factors were compared between LTS (total of 91 patients) v. STS-1, and LTS (subgroup of 80 patients) v. STS-2. We included glial fibrillary acidic protein (GFAP), O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation, isocitrate dehydrogenase 1 (IDH-1); furthermore, the proliferation index was analyzed (Ki-67/MIB-1). RESULTS: IDH-1 and decreased Ki-67 were numerically associated with LTS but the difference was only significant compared to STS-1 (n.s. v. STS-2). LTS was associated with MGMT promoter hypermethylation (p = 0.013 and p = 0.022) and GFAP expression (p < 0.001 and p = 0.001). Positivity for both factors combined compared to negativity for one factor occurred more often in the LTS group (p = 0.002 and p = 0.006); negativity for both factors combined did not occur in the LTS group. CONCLUSION: In this retrospective analysis, GFAP expression and MGMT promoter methylation were associated with LTS. Given the hypothesis-generating nature of our study, these observations should be confirmed in prospective clinical trials. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13014-022-01984-w. BioMed Central 2022-01-24 /pmc/articles/PMC8785532/ /pubmed/35073955 http://dx.doi.org/10.1186/s13014-022-01984-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Sommerlath, Vivien N.
Buergy, Daniel
Etminan, Nima
Brehmer, Stefanie
Reuss, David
Sarria, Gustavo R.
Guiot, Marie-Christin
Hänggi, Daniel
Wenz, Frederik
Petrecca, Kevin
Giordano, Frank A.
Molecular features of glioblastomas in long-term survivors compared to short-term survivors—a matched-pair analysis
title Molecular features of glioblastomas in long-term survivors compared to short-term survivors—a matched-pair analysis
title_full Molecular features of glioblastomas in long-term survivors compared to short-term survivors—a matched-pair analysis
title_fullStr Molecular features of glioblastomas in long-term survivors compared to short-term survivors—a matched-pair analysis
title_full_unstemmed Molecular features of glioblastomas in long-term survivors compared to short-term survivors—a matched-pair analysis
title_short Molecular features of glioblastomas in long-term survivors compared to short-term survivors—a matched-pair analysis
title_sort molecular features of glioblastomas in long-term survivors compared to short-term survivors—a matched-pair analysis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8785532/
https://www.ncbi.nlm.nih.gov/pubmed/35073955
http://dx.doi.org/10.1186/s13014-022-01984-w
work_keys_str_mv AT sommerlathvivienn molecularfeaturesofglioblastomasinlongtermsurvivorscomparedtoshorttermsurvivorsamatchedpairanalysis
AT buergydaniel molecularfeaturesofglioblastomasinlongtermsurvivorscomparedtoshorttermsurvivorsamatchedpairanalysis
AT etminannima molecularfeaturesofglioblastomasinlongtermsurvivorscomparedtoshorttermsurvivorsamatchedpairanalysis
AT brehmerstefanie molecularfeaturesofglioblastomasinlongtermsurvivorscomparedtoshorttermsurvivorsamatchedpairanalysis
AT reussdavid molecularfeaturesofglioblastomasinlongtermsurvivorscomparedtoshorttermsurvivorsamatchedpairanalysis
AT sarriagustavor molecularfeaturesofglioblastomasinlongtermsurvivorscomparedtoshorttermsurvivorsamatchedpairanalysis
AT guiotmariechristin molecularfeaturesofglioblastomasinlongtermsurvivorscomparedtoshorttermsurvivorsamatchedpairanalysis
AT hanggidaniel molecularfeaturesofglioblastomasinlongtermsurvivorscomparedtoshorttermsurvivorsamatchedpairanalysis
AT wenzfrederik molecularfeaturesofglioblastomasinlongtermsurvivorscomparedtoshorttermsurvivorsamatchedpairanalysis
AT petreccakevin molecularfeaturesofglioblastomasinlongtermsurvivorscomparedtoshorttermsurvivorsamatchedpairanalysis
AT giordanofranka molecularfeaturesofglioblastomasinlongtermsurvivorscomparedtoshorttermsurvivorsamatchedpairanalysis